GlassScriptPhysician profile
Stephen Alan South
NPI 1043237472
$624,185.22
in general payments reported to CMS, 2019-2025
66 companies · $83K in 2025
The $83K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $116K · 2021: $80K · 2022: $80K · 2023: $56K · 2024: $58K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Food and Beverage: $8,087 · Travel and Lodging: $6,294 · Consulting Fee: $735 · Honoraria: $500 · Education: $68.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $181,795.00 |
| Food and Beverage | $8,086.92 |
| Travel and Lodging | $6,294.32 |
| Consulting Fee | $735.00 |
| Honoraria | $500.00 |
| Education | $68.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $514,344.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36,761.85 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $28,991.66 | 2019-2024 | Xarelto |
| Amgen INC. | $16,102.12 | 2019-2025 | Tepezza, Prolia, Evenity |
| Madrigal Pharmaceuticals | $10,998.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Valeritas, INC. | $3,289.52 | 2019 | |
| Horizon Therapeutics Plc | $2,218.66 | 2020-2023 | Tepezza |
| Novo Nordisk INC | $1,381.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Cequr Corporation | $967.72 | 2022-2025 | Cequr Simplicity |
| Abbvie INC. | $893.31 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $718.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $665.86 | 2019-2024 | Airsupra |
| Intra-Sana Laboratories | $597.58 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbott Laboratories | $499.82 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $498.83 | 2019-2025 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen South listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.